Total Funding
57
Total FundingSeries B raised
Growth Score
pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
120324
Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications
Acquired by 
Biohaven Pharmaceutical
- David A. Spiegel: President of Kleo Laboratories
About the Company
Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). They believe their technology represents a breakthrough in safer, more efficacious, and more convenient treatment options.
